Mina Farahani, MD
Ophthalmology · Boston, MANPI 1245650860
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $174,021 of the $227,100 with a category attached, or 76.6%. 24 manufacturers reported payments, led by Tarsus Pharmaceuticals, Inc. at 30.3% of the total. 2025 is the largest year on record at $91,481, more than ten times the $409 reported in 2019. Among ophthalmology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 313 payments — averaging $725.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tarsus Pharmaceuticals, Inc.$69K
- Bausch & Lomb Americas Inc.$38K
- GSK$36K
- Sun Pharmaceutical Industries Inc.$31K
- Sight Sciences, Inc.$29K
- Oyster Point Pharma, Inc.$16K
- plus $9K from 18 others
Across 3 payments — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$6K
What the payments were for
- Consulting fees$31,62114%
- Speaking & faculty fees$174,02177%
- Travel & lodging$10,2445%
- Food & beverage$11,0055%
- Education$180%
- Entertainment$1910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. | 54 | $68,762 |
| Bausch & Lomb Americas Inc. | 50 | $38,174 |
| GSK | 19 | $35,919 |
| Sun Pharmaceutical Industries Inc. | 46 | $30,707 |
| Sight Sciences, Inc. | 43 | $29,026 |
| Oyster Point Pharma, Inc. | 23 | $15,687 |
| Nordic Pharma, Inc. | 1 | $2,100 |
| Rxsight Inc | 6 | $1,905 |
| Sanofi | 1 | $1,521 |
| Alcon | 20 | $722 |
| Novartis | 8 | $618 |
| Dompe US, Inc. | 9 | $380 |
| Glaukos Corporation | 7 | $260 |
| AbbVie(2 entities) | 10 | $256 |
| Optos, Inc. | 1 | $191 |
| Harrow Eye, LLC | 2 | $157 |
| Carl Zeiss Meditec USA, Inc. | 1 | $142 |
| Mallinckrodt Hospital Products Inc. | 4 | $140 |
| Eyepoint US, Inc. | 1 | $124 |
| Apellis Pharmaceuticals, Inc. | 1 | $118 |
| Aerie Pharmaceuticals, Inc. | 1 | $86 |
| ANI Pharmaceuticals, Inc. | 3 | $70 |
| Thea Pharma Inc. | 1 | $18 |
| Johnson & Johnson Vision Care, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XDEMVY$58,724
- MIEBO$36,336
- BLENREP$34,538
- XIIDRA$34,477
- CEQUA$30,131
- TYRVAYA$15,140
- TEARCARE SYSTEM$13,864
- TearCare SmartLid$9,114
- TEARCARE(TM) (2.2) SYSTEM KIT$9,114
- OMNI(R) SURGICAL SYSTEM (US)$5,826
- SION SURGICAL INSTRUMENT$5,451
- Lacrifill$2,100
- RXSIGHT CONTACT LENS$1,866
- RXSIGHT INJECTOR CARTRIDGE$1,866
- RXSIGHT INJECTOR HANDPIECE$1,866
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$1,866
- LIGHT ADJUSTABLE LENS (LAL)$1,717
- BLINK NUTRITEARS$700
- PANORAMIC OPHTHALMOSCOPE$381
- OCT OPHTHALMOSCOPE$381
How this compares
$227,100 in reported general payments places this provider in the 95th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 13 | $360,897 |
| CequaCyclosporine | 106 | $124,477 |
| TyrvayaVarenicline Tartrate | 112 | $86,472 |
| XiidraLifitegrast | 56 | $67,888 |
| RestasisCyclosporine | 59 | $62,123 |
| MieboPerfluorohexyloctane/Pf | 50 | $42,326 |
| XdemvyLotilaner | 21 | $38,834 |
| Cyclosporine | 55 | $27,521 |
| VevyeCyclosporine | 18 | $15,018 |
| LumiganBimatoprost | 15 | $6,634 |
| Prednisolone Acetate | 155 | $5,087 |
| Loteprednol Etabonate | 15 | $2,010 |
| Brimonidine Tartrate | 20 | $1,177 |
| ValacyclovirValacyclovir Hcl | 39 | $1,106 |
| Doxycycline Monohydrate | 47 | $809 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $380 | $360,89713 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $30,707 | $124,477106 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $38,174 | $110,213106 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $15,687 | $86,472112 claims |
| AbbVieRestasis, Lumigan | $256 | $68,75674 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $68,762 | $38,83421 claims |
| Harrow Eye, LLCVevye | $157 | $15,01818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 653 ophthalmology providers in Massachusetts.
Other ophthalmology in Boston
- Rishi SinghBoston$1.7M
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Dean EliottBoston$250K
- Jia YinBoston$173K
- John MillerBoston$106K
- Elizabeth RossinBoston$101K
- Suzanne FreitagBoston$96K
- Nimesh PatelBoston$94K
- Michael RaizmanBoston$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.